

Abbreviated Curriculum Vitae

Dr Cecil Ross MBBS MD

St. John's Medical College Hospital, Department of Hematology, Sarjapur Road, Koramangala, Bangalore-560034, Karnataka, India.	FAX: +91-80-25503697 Ph: +91-80-25531984 E Mail ID: cecil.ross@stjohns.in
---	---

Education and Training:

Name and Location of Institution	Degree and Year Awarded	Area of Study
St. John's Medical College, Bangalore	MBBS	
Government Medical College, Bellary	MD	Gen. Medicine
CMCH-Vellore	Fellow	Hematology
Royal Free Hospital - London	Fellow	Hematology
St. Louis University –Missouri, USA	Fellow	Hematology

Professional Experience : KMC MRC No: 22137 Currently working as Professor and Head Medicine Unit I and Hematology St. Johns Medical College Hospital, Bangalore - 560034

Research Funding

Haemoglobin (Past)	Jai Vignan Mission Project I and II Indian Council of Medical Research on community control of Thalassemia & Sickle Cell Anaemia 2004-2010
Leukemic Stem Cell (Present)	CML DBT Glue Grant SERB Grant
Haemophilia, (Present)	Haemophilia DBT Grant
Clinical Trials	Hemophilia, Blood Cancer, Rare Bleeding disorders

AFFILIATIONS

1. Life member, Association of Physicians of India Central Body.
2. Life member, Association of Physicians of India Karnataka chapter
3. Life member, Indian Society of Haematology & Blood Transfusion
4. TwinPartnerSt. LouisUniversity Coagulation Consultants. St. Louis MO, USA
5. Founder Member Indian Society of Hematology and Blood Transfusion Karnataka Chapter
6. Founder Member Indian Hemophilia and Allied Disorders Group

AWARDS:

1. Twin of the year award for 2001 by the World Hemophilia Federation- Montreal Canada
2. API Oration 2014

EXAMINERSHIPS:

a) MBBS/MD

1. MBBS / MD (Medicine) M.G. Ramachandra Health University - Chennai (Madras) since 1993
2. MBBS / MD (Medicine) Rajiv Gandhi Health University - Bangalore. since 1997
3. DM (Hematology) Examiner: Bombay University for DM hematology.

b) DNBE (National Board of Examinations)

1. Panel Member - DNBE Selection committee, St. Martha's Hospital, Since Jan. 2008.
2. Phd Examiner (MGR Medical University)

Publications in the last 3 years: 2016-18

1. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. F. Peyvandi, P.M. Mannucci, I. Garagiola, A. El- Beshlawy, M. Elalfy, V. Ramanan, P. Eshghi, S. Hanagavadi, R. Varadarajan, M. Karimi, M.V. Manglani, C. Ross, et al N Engl J Med 2016;374:2054-64.
2. Efficacy of Human Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and to Prevent Bleeding during and after Surgery in Subjects with Congenital Fibrinogen Deficiency
Bruce A. Schwartz, Cecil Ross, Bella Madan, Toshko JelevevLissitchkov, Mehran Karimi, Sigurd Knaub and Flora Peyvandi
Blood 2016 128:1404;
3. Pharmacokinetic (PK) comparison of two fibrinogen concentrates in patients with congenital fibrinogen deficiency: final analysis
Haemophilia 2016: 22; S4 P122
B Schwartz, C Ross, S Rangarajan, M Karimi, S Knaub and F Peyvandi
4. Efficacy and safety of a new human fibrinogen concentrate inpatients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial. Toshko Lissitchkov Bella Madan, Claudia DjambasKhayat, NadezhdaZozulya, Cecil Ross,Mehran Karimi, KaanKavakli, Guillermo R. De Angulo, AbdulkareemAlmomen, Bruce A. Schwartz, Cristina Solomon, Sigurd Knaub, and Flora Peyvandi TRANSFUSION , November 2017 Volume 00

5. Pharmacokinetics of fibrinogen concentrate and efficacy in treating acute bleeding in paediatric patients with congenital fibrinogen deficiency: M. Karimi, C. Ross, G.R. De Angulo, B.A. Schwartz, C. Solomon, F. Peyvandi. *Res PractThrombHaemost.* 2017;1(Suppl. 1):p642. Abstract PB 1753 presented as a poster at ISTH 2017, Berlin Germany
6. On-demand treatment with fibrinogen concentrate in acute bleeding and for surgery in patients with congenital fibrinogen deficiency: C. Ross, B. Madan, M. Karimi, T. Lissitchkov, B.A. Schwartz, S. Knaub, F. Peyvandi, *Res PractThrombHaemost.* 2017;1(Suppl. 1):p641. Abstract PB 1751 presented as a poster at ISTH 2017, Berlin Germany
7. Pharmacokinetics, clot strength and safety of a newfibrinogen concentrate: randomized comparison with activecontrol in congenital fibrinogen deficiency. Ross C, Rangarajan S, Karimi M, Toogeh G, Apte S, Lissitchkov T, Acharya S, Manco-Johnson MJ, Srivastava A, Brand B, Schwartz BA, Knaub S, Peyvandi F. *J Thromb Haemost* 2018;Thromb Haemost 2018; 16: 1–9
8. Molecular insights of inhibition in sickle hemoglobin polymerization upon glutathionylation: hydrogen/deuterium exchange mass spectrometry and molecular dynamics simulation-based approach
Rajdeep Das, Amrita Mitra, Gopa Mitra, Dibyajyoti Maity, Vijay Bhat, Debnath Pal, Cecil Ross, Anura V. Kurpad and Amit Kumar Mandal: *Biochemical Journal* (2018) 475 2153–2166
9. Safety and efficacy of intravenous immunoglobulin (Flebogamma R 10% DIF) in patients with immune thrombocytopenic purpura. Shashikant Apte, Jordi Navarro-Puerto, Sharat Damodar, Vijay Ramanan, JosephJohn, GiraldoKato, Cecil Ross, Chirag Shah, Marcela Torres, Chieh-Lin ‘Kathy’ Fu, Karen Rucker, Paul Pinciario, Gladis Barrera, Maria Esperanc,a Aragon´ es & JaumeAyguaसानosa Future Medicine Immunotherapy Published online: 30 November 2018 reprints@futuremedicine.com